Alopecia from CDK 4/6 inhibitors worsens quality of life in breast cancer patients.
4 citations
,
October 2018 in “Asia-Pacific Journal of Clinical Oncology” CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
28 citations
,
July 2017 in “Expert Review of Anticancer Therapy” Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
Abemaciclib can cause skin, hair, and nail problems, leading some patients to stop using it.